Viewing Study NCT06424080



Ignite Creation Date: 2024-06-16 @ 11:48 AM
Last Modification Date: 2024-10-26 @ 3:30 PM
Study NCT ID: NCT06424080
Status: RECRUITING
Last Update Posted: 2024-06-04
First Post: 2024-05-13

Brief Title: Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors
Sponsor: Menoufia University
Organization: Menoufia University

Study Overview

Official Title: Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors
Status: RECRUITING
Status Verified Date: 2024-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: partial nephrectomy offers lower renal function impairment and equivalent oncological survival outcomes compared with radical nephrectomy in those with T1 tumors

As urology has embraced the gradual shift from open to minimally invasive surgery MIS PN is being completed more often by laparoscopic and robotic methods

The first laparoscopic transperitoneal partial nephrectomy was reported in 1993 by Winfield with the retroperitoneal approach introduced 1 year later With advancing robotic technology and the development of the DaVinci system urologists began to explore the realm of robotic-assisted urologic surgery In 2004 Gettman et al published a paper describing their experience with robotic-assisted laparoscopic partial nephrectomy

Moreover robotic assisted partial nephrectomy RAPN and laparoscopic partial nephrectomy LPN seems to be significantly better than OPN in terms of perioperative complications estimated blood loss and hospital stay Conversely transfusion rate ischemia time change in estimated glomerular filtration rate and early cancer outcomes are similar between the two approaches International guidelines recommend the use of both approaches according to the surgeon and patient preferences

so we are plaining to do the study comparing between RAPN and LPN regarding feasibility and ability of both techniques
Detailed Description: Renal cell carcinoma RCC represents a significant burden of malignancy Over the past 2-3 decades the incidence of kidney cancer has steadily increased all around the world The EUA Guidelines suggested that surgery is the only curative treatment for localized renal cell carcinoma

Surgical treatment of RCC either radical or partial nephrectomy is related to the clinical stage of the disease and to the general condition of the patient Modern medical imaging has further revolutionized the role of PN due to the increasing volume of incidentally diagnosed small renal masses

Indeed partial nephrectomy offers lower renal function impairment and equivalent oncological survival outcomes compared with radical nephrectomy in those with T1 tumors

As urology has embraced the gradual shift from open to minimally invasive surgery MIS PN is being completed more often by laparoscopic and robotic methods

The first laparoscopic transperitoneal partial nephrectomy was reported in 1993 by Winfield with the retroperitoneal approach introduced 1 year later With advancing robotic technology and the development of the DaVinci system urologists began to explore the realm of robotic-assisted urologic surgery In 2004 Gettman et al published a paper describing their experience with robotic-assisted laparoscopic partial nephrectomy

Moreover robotic assisted partial nephrectomy RAPN and laparoscopic partial nephrectomy LPN seems to be significantly better than OPN in terms of perioperative complications estimated blood loss and hospital stay Conversely transfusion rate ischemia time change in estimated glomerular filtration rate and early cancer outcomes are similar between the two approaches International guidelines recommend the use of both approaches according to the surgeon and patient preferences

so we are plaining to do the study comparing between RAPN and LPN regarding feasibility and ability of both techniques

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None